Understanding the Risks of Weight Loss Injections
Overview of GLP-1 Receptor Agonists
GLP-1 receptor agonists are medications commonly prescribed for managing type 2 diabetes and obesity. These drugs, including Wegovy, Ozempic, and Mounjaro, have gained significant popularity, particularly following the FDA’s approval of an oral version of Wegovy for weight loss in December 2025.
Potential Side Effects
While these injections offer transformative benefits for many individuals, they are not without risks. One serious but rare side effect that has drawn attention is acute pancreatitis, characterized by inflammation of the pancreas. Symptoms may include sudden abdominal pain, nausea, and swelling.
Recent Developments in Guidance
U.K. Regulatory Response
In light of an increase in reports of acute pancreatitis, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom has updated its guidance on weight-loss injections. This update follows the monitoring of adverse reactions through the Yellow Card scheme.
Prevalence of Reports
Data indicates that between 2024 and 2025, approximately 1.6 million adults in England, Wales, and Scotland utilized GLP-1 medications for weight loss. From 2007 to October 2025, there were 1,296 Yellow Card reports associated with pancreatitis linked to GLP-1 receptor agonists, including 19 fatal cases.
Expert Insights on Weight Loss Injections
Medical Perspectives
To gain deeper insights into the implications of weight loss injections and the associated risks, Medical News Today consulted three medical experts:
– Hector Perez, MD, a board-certified bariatric surgeon at Renew Bariatrics and advisor at BestSurgeons.
– Mir Ali, MD, bariatric surgeon and medical director at MemorialCare Surgical Weight Loss Center in Fountain Valley, CA.
– David Cutler, MD, a board-certified family medicine physician at Providence Saint John’s Health Center in Santa Monica, CA.
These professionals emphasized the importance of being informed about the risks of acute pancreatitis and recognizing its symptoms, while assuring that such occurrences are uncommon.